As Biotechnology companies, ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) and EyePoint Pharmaceuticals Inc. (NASDAQ:EYPT) are our subject to contrast. And more specifically their institutional ownership, profitability, risk, dividends, analyst recommendations, earnings and valuation.
Valuation & Earnings
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|ACADIA Pharmaceuticals Inc.||223.81M||17.30||245.19M||-1.44||0.00|
|EyePoint Pharmaceuticals Inc.||3.06M||76.62||80.31M||-1.35||0.00|
Table 1 shows gross revenue, earnings per share (EPS) and valuation of the two companies.
Table 2 hightlights the return on equity, return on assets and net margins of the two companies.
|Net Margins||Return on Equity||Return on Assets|
|ACADIA Pharmaceuticals Inc.||-109.55%||-77.1%||-66.6%|
|EyePoint Pharmaceuticals Inc.||-2,624.51%||-414.6%||-142.9%|
Risk & Volatility
ACADIA Pharmaceuticals Inc. has a beta of 3.28 and its 228.00% more volatile than Standard & Poor’s 500. EyePoint Pharmaceuticals Inc.’s 2.02 beta is the reason why it is 102.00% more volatile than Standard & Poor’s 500.
ACADIA Pharmaceuticals Inc. has a Current Ratio of 8.8 and a Quick Ratio of 8.8. Competitively, EyePoint Pharmaceuticals Inc.’s Current Ratio is 2.6 and has 2.6 Quick Ratio. ACADIA Pharmaceuticals Inc.’s better ability to pay short and long-term obligations than EyePoint Pharmaceuticals Inc.
ACADIA Pharmaceuticals Inc. and EyePoint Pharmaceuticals Inc. Ratings and Recommendations are available in the next table.
|Sell Ratings||Hold Ratings||Buy Ratings||Rating Score|
|ACADIA Pharmaceuticals Inc.||0||3||6||2.67|
|EyePoint Pharmaceuticals Inc.||0||0||0||0.00|
ACADIA Pharmaceuticals Inc.’s average price target is $33.89, while its potential upside is 25.94%.
Institutional & Insider Ownership
Institutional investors owned 98.64% of ACADIA Pharmaceuticals Inc. shares and 62.3% of EyePoint Pharmaceuticals Inc. shares. Insiders owned 0.1% of ACADIA Pharmaceuticals Inc. shares. Comparatively, 0.5% are EyePoint Pharmaceuticals Inc.’s share owned by insiders.
In this table we show the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.
|Performance (W)||Performance (M)||Performance (Q)||Performance (HY)||Performance (Y)||Performance (YTD)|
|ACADIA Pharmaceuticals Inc.||13.05%||17.87%||30.78%||86.2%||16.84%||66.05%|
|EyePoint Pharmaceuticals Inc.||-2.21%||21%||28.64%||25%||150%||40.21%|
For the past year ACADIA Pharmaceuticals Inc.’s stock price has bigger growth than EyePoint Pharmaceuticals Inc.
On 8 of the 11 factors ACADIA Pharmaceuticals Inc. beats EyePoint Pharmaceuticals Inc.
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis. It is also developing pimavanserin as a treatment for dementia-related psychosis and as an adjunctive treatment for schizophrenia that are in phase III clinical trials; and pimavanserin as an adjunctive treatment for major depressive disorder. ACADIA Pharmaceuticals Inc. was founded in 1993 and is headquartered in San Diego, California.
EyePoint Pharmaceuticals, Inc., a specialty biopharmaceutical company, engages in developing and commercializing ophthalmic products in indications with high unmet medical need to help improve the lives of patients with eye disorders. The company has developed three FDA-approved sustained-release treatments in ophthalmology, including DEXYCU (dexamethasone intraocular suspension), which is administered as a single intraocular dose at the end of ocular surgery for postoperative inflammation; ILUVIEN (fluocinolone acetonide intravitreal implant), a micro-insert for diabetic macular edema; and Retisert (fluocinolone acetonide intravitreal implant) for posterior uveitis. Its lead product candidate is Durasert, (fluocinolone acetonide intravitreal implant), a micro-insert for the treatment of non-infectious uveitis affecting the posterior segment of the eye. In addition, the company’s pre-clinical development program focuses on using its core Durasert platform technology to deliver drugs to treat wet age-related macular degeneration, glaucoma, osteoarthritis, and other diseases. It has license agreements with Bausch and Lomb for Retisert product; a license agreement with Alimera for ocular applications of the ILUVIEN device; and a collaboration agreement with Pfizer for the Durasert device delivering latanoprost. The company was formerly known as pSivida Corp. and changed its name to EyePoint Pharmaceuticals, Inc. in March 2018. EyePoint Pharmaceuticals, Inc. was founded in 1987 and is headquartered in Watertown, Massachusetts.